Binding Site Announces Hevylite® Assay Patent Approval
News Mar 20, 2014
Measurement of immunoglobulin heavy/light chains allows, for the first time, accurate calculation of immunoglobulin heavy/light chain ratios, e.g. IgGκ/IgGλ, an inventive step recognised by Patent Offices in the USA, Europe and Japan.
In continuation of Binding Site’s innovative approach to protein detection in B cell disorders, patents covering the specific Hevylite® antibodies which recognise conformational epitopes, methods to concurrently measure heavy/light chain and free light chains together in multiplex assays, and production of heavy/light chain ratios using ELISA, Flow Cytometry or bead based assays have also been granted.
Hevylite® assays to measure the concentration of each immunoglobulin subtype i.e. IgGκ, IgGλ, IgAκ, IgAλ, IgMκ, IgMλ are CE marked and FDA cleared. The assays are currently in routine use in a number of countries, are being evaluated by many institutions worldwide and have been the subject of more than 20 papers and around 200 poster publications. These new assays overcome many of the issues seen when using traditional electrophoresis methods such as lower sensitivity and co-migration of bands, plus it gives information about the uninvolved heavy/light chain pair, e.g. IgAλ in an IgAκ myeloma patient.
Hevylite® is now incorporated into prestigious guidelines published by the British Committee for Standards in Haematology. This inclusion reflects the increasing number of publications showing the benefits of Hevylite® in a laboratory and clinical setting. Download your free copy of the BCSH Guidelines here
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.